Table 3 Frequency of the different treatment presentations from 2015 to 2020a
From: Prevalence of treated patients with Alzheimer’s disease: current trends and COVID-19 impact
Treatment and dose for the mean number of patients treated monthly | Year | Total mean (2015–2020) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | |||||||||
N | % | N | % | N | % | N | % | N | % | N | % | N | % | |
Donezepil 10 mg | 605 | 17% | 689 | 18% | 779 | 20% | 819 | 21% | 865 | 22% | 855 | 22% | 922 | 20% |
Memantine 20 mg | 661 | 18% | 739 | 19% | 802 | 20% | 791 | 20% | 748 | 19% | 739 | 19% | 896 | 19% |
Rivastigmine Patch 9.5 mg | 852 | 24% | 826 | 21% | 790 | 20% | 710 | 18% | 691 | 17% | 705 | 18% | 915 | 20% |
Donezepil 5 mg | 71 | 2% | 100 | 3% | 132 | 3% | 180 | 5% | 218 | 6% | 218 | 6% | 184 | 4% |
Rivastigmine Patch 13.3 mg | 90 | 2% | 181 | 5% | 196 | 5% | 194 | 5% | 190 | 5% | 182 | 5% | 207 | 4% |
Rivastigmine Patch 4.6 mg | 155 | 4% | 159 | 4% | 160 | 4% | 173 | 4% | 173 | 4% | 180 | 5% | 200 | 4% |
Memantine 10 mg | 53 | 1% | 69 | 2% | 86 | 2% | 117 | 3% | 165 | 4% | 160 | 4% | 130 | 3% |
Donezepil 10 mg + Memantine 20 mg | 128 | 4% | 143 | 4% | 128 | 3% | 125 | 3% | 133 | 3% | 153 | 4% | 162 | 3% |
Memantine 20 mg + Rivastigmine Patch 9.5 mg | 227 | 6% | 171 | 4% | 150 | 4% | 132 | 3% | 129 | 3% | 120 | 3% | 185 | 4% |
Galantamine 24 mg | 179 | 5% | 168 | 4% | 157 | 4% | 135 | 3% | 119 | 3% | 109 | 3% | 173 | 4% |
Others | 572 | 16% | 607 | 16% | 594 | 15% | 544 | 14% | 524 | 13% | 491 | 13% | 666 | 14% |
Total | 3593 | 100% | 3852 | 100% | 3974 | 100% | 3920 | 100% | 3955 | 100% | 3912 | 100% | 4640 | 100% |